Skip to main content
峆一药业 logo

峆一药业 — Investor Relations & Filings

Ticker · 920478 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2025-04-17 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920478

About 峆一药业

http://www.heryipharma.com/

Anhui Heyi Pharmaceutical Co., Ltd. specializes in the research, development, production, and sales of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company focuses on providing high-quality chemical products for various therapeutic areas, including cardiovascular, central nervous system, and anti-infective treatments. With a strong emphasis on technological innovation and quality control, it operates advanced manufacturing facilities that adhere to international standards. Its product portfolio includes key intermediates for widely used medications, supporting both domestic and global pharmaceutical supply chains. The company leverages its expertise in complex chemical synthesis to offer customized solutions and reliable supply to its partners in the life sciences sector.

Recent filings

Filing Released Lang Actions
关于预计2025年度公司向银行申请授信额度的公告
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding the company's plan to apply for a credit facility (授信额度) from financial institutions, including details about the amount, purpose, authorization, and board meeting resolution. It does not contain financial statements or detailed financial performance data. The document is short (827 characters) and focuses on financing activities. Therefore, it fits the category of Capital/Financing Update (CAP).
2025-04-17 Chinese
2024年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is a detailed internal control evaluation report for the fiscal year ending December 31, 2024, issued by the company's board and management. It discusses the company's internal control systems, evaluation scope, methodology, findings on financial and non-financial internal control deficiencies, and improvement measures. The content is focused on internal control effectiveness and compliance with regulatory internal control standards, including detailed descriptions of control areas such as organizational structure, human resources, financial reporting, and risk management. There is no indication that this is an annual report, earnings release, or other financial statement. It is not a brief announcement or a certification letter but a substantive report on internal control evaluation. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and internal control evaluation results. The document length (9528 characters) supports it being a full report rather than a short announcement. Therefore, the appropriate classification is AR with high confidence. FY 2024
2025-04-17 Chinese
第四届监事会第二十四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 24th meeting of the 4th Supervisory Board of Anhui Xuyi Pharmaceutical Co., Ltd. It includes approvals of various reports such as the 2024 Supervisory Board Work Report, 2024 Annual Report and Summary, 2024 Financial Final Report, 2025 Financial Budget Report, audit reports, internal control reports, and other related documents. The document references these reports as being disclosed separately on the Beijing Stock Exchange information disclosure platform, indicating that this document itself is not the full reports but a meeting resolution announcement. The document also includes voting results and procedural details of the Supervisory Board meeting. Given the nature of the content—meeting resolutions and approvals rather than the reports themselves—this fits best under the category of Regulatory Filings (RNS), which is the fallback for announcements and disclosures that do not constitute the full reports themselves. The document length is under 5,000 characters, consistent with an announcement rather than a full report. Therefore, the classification is RNS with high confidence.
2025-04-17 Chinese
会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the appointment and evaluation of the company's auditor for the 2024 fiscal year. It details the auditor's qualifications, risk management, audit plan, quality control, and independence assessment. There is no actual audit report or financial statements included, only information about the auditor and the audit engagement. The document length is 2653 characters, which is relatively short and consistent with an announcement rather than a full audit report. The content matches the description of an Audit Report / Information filing, which includes standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests, excluding full annual reports. Therefore, the document should be classified as an Audit Report / Information (AR). FY 2024
2025-04-17 Chinese
募集资金存放与实际使用情况鉴证报告
Regulatory Filings
2025-04-17 Chinese
国元证券股份有限公司关于安徽峆一药业股份有限公司关联交易的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed opinion from a sponsoring securities firm regarding a related-party transaction for Anhui Xieyi Pharmaceutical Co., Ltd. It includes information about the related parties, transaction pricing, fairness, decision-making procedures, and the sponsor's verification opinion. The document references regulatory rules related to securities issuance and listing on the Beijing Stock Exchange. It is not a financial report, earnings release, or management discussion, but rather a formal verification and opinion on a specific transaction related to securities issuance. This type of document fits best under Regulatory Filings (RNS) as it is a compliance and verification statement related to regulatory requirements, not a standalone audit report or annual report.
2025-04-17 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.